AstraZeneca Stomach Cancer Drug Trial Highlights New Clinical Research Findings

Author : Shruti Sinha | Published On : 26 Oct 2026

The AstraZeneca Stomach Cancer Drug Trial has brought attention to a potential new treatment approach for patients with advanced stomach and related cancers. The Phase III CLARITY-Gastric01 study evaluated sonesitatug vedotin, also known as Sone-Ve, an investigational targeted medicine.

The trial compared Sone-Ve with treatment selected by physicians for patients whose cancer had progressed after earlier therapies. Researchers reported a 42% reduction in the risk of death across the overall study population. Median overall survival was 10.6 months in the Sone-Ve group, compared with 6.4 months in the comparison group. <Cite refs={["turn509573search0"]}/>

The medicine targets CLDN18.2, a protein expressed in certain gastric and related cancers. This research reflects ongoing efforts to develop targeted therapies that may offer additional options for people with advanced cancer.

Although the survival results are notable, the findings require careful interpretation. The independently assessed progression-free survival endpoint did not achieve statistical significance, and Sone-Ve remains an investigational treatment.

The study adds important information to ongoing oncology research and may help guide further evaluation of targeted therapies for advanced stomach cancer.